Acelyrin Inc (NAS:SLRN)
$ 3.25 -0.07 (-2.11%) Market Cap: 326.06 Mil Enterprise Value: -222.73 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 20/100

Q2 2024 ACELYRIN Inc Earnings Call Transcript

Aug 13, 2024 / 09:00PM GMT
Release Date Price: $4.76 (+4.39%)
Operator

Good afternoon, and welcome to the ACELYRIN Inc Conference Call to discuss the company's second quarter 2024 financial results and other corporate updates. This conference call is being recorded today, August 13, 2024.

I would now like to turn the conference call over to Tyler Marciniak, Vice President of Investor Relations and Corporate Affairs. Tyler?

Tyler Marciniak
ACELYRIN Inc - Vice President of Investor Relations and Corporate Affairs

Thank you, Carmen. Good afternoon, everyone, and thank you for joining us. Before we begin, I'd like to remind you that this conference call may contain forward-looking statements such as those related to progress of our clinical trials and anticipated data readouts, our future financial and operating results and projected cash runway, and our ability to commercialize our product candidates. These forward-looking statements involve risks and uncertainties that could cause our actual results and events to differ materially.

We would urge you to review the Risk Factors section of our Form 10-Q for the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot